Skip to main content
. 2020 Nov 10;12(11):3322. doi: 10.3390/cancers12113322

Figure 9.

Figure 9

Crizotinib disposition in the blood components following standard dosing (250 mg twice daily) of a single NSCLC patient at the start (day 1) of treatment (A). Blood compartment disposition in time after 1, 2, 3, and 6 months of crizotinib treatment (B).